We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful treatment of severe cholinergic urticaria with omalizumab: A case report.
- Authors
Yamasaki, Aoi; Oda, Yoshiko; Tanizaki, Hideaki; Otsuka, Toshihiro; Fukunaga, Atsushi; Nishigori, Chikako; Moriwaki, Shinichi
- Abstract
Omalizumab, a humanized anti‐IgE monoclonal antibody, has been approved in Japan for the treatment of antihistamine‐resistant idiopathic chronic spontaneous urticaria. We herein report a 27‐year‐old Japanese woman suffering from a 2‐year history of severe cholinergic urticaria (sweat allergy‐type), which was unresponsive to various H2‐antihistamines and other medication but was successfully treated with omalizumab. The patient showed rapid and marked reduction in her symptoms of urticaria after the first injection of omalizumab (300 mg). She has been receiving omalizumab treatment quaque 4 weeks (q4w) three times and subsequent q6w six times, followed by maintenance treatment q8w without any adverse reactions for a total of 68 weeks. Although further large‐scale clinical investigation is needed, omalizumab may be a beneficial therapeutic remedy for patients with intractable, chronic inducible urticaria including cholinergic urticaria. Our case with severe cholinergic urticaria showed rapid improvement after the treatment using omalizumab. Omalizumab may be a beneficial therapeutic remedy for patients with intractable, chronic inducible urticaria including cholinergic urticaria.
- Subjects
TREATMENT of urticaria; ANTI-immunoglobulin E autoantibodies; ANTIHISTAMINES; URTICARIA; ALLERGIES
- Publication
Journal of Cutaneous Immunology & Allergy, 2019, Vol 2, Issue 1, p31
- ISSN
2574-4593
- Publication type
Case Study
- DOI
10.1002/cia2.12043